A meta-analysis of compound kushen injection in the treatment for advanced hepatocellular carcinomas

VernacularTitle:复方苦参注射液对中晚期肝癌疗效meta分析
Author: Yuwei JIANG ; Bo YANG ; Zhiguo RAO
Publication Type:Journal Article
Keywords: SOPHORA FLAVESCENS/TU; COMPOUNDS (TCD); INJECTIO; Liver neoplasms/ZD; Meta-analysis
From: Journal of Chinese Physician 2015;17(6):803-806
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficacy and safety of compound kushen injection (CKI)in the treatment for patients with advanced liver cancers.Methods Relevantly randomized controlled trials from China National Knowledge Infrastructure (CNKI),Chinese Science and Technology Journal Database (VIP),Wanfang Data,and Pubmed were searched until November,2014.Randomized controlled trials (RCTs) of supportive care compared with combined therapy of CKI in the treatment for patients with advanced liver cancers were included.The methodological quality of RCTs was assessed independently with bias risk according to the Cochrane collaboration.All data were analyzed with the Review Manager 5.3.Results Eight RCTs involving 472 patients were included.The meta-analysis results suggested that the shortterm efficacy of the treatment group be higher (P =0.008) and that the pain relief be a significant benefit in the treatment group (P ＜0.01).Adverse reactions were not observed.Conclusions CKI is an effective and safe adjuvant drug for advanced liver cancers.